Relief Therapeutics Holding SA

Equities

RLF

CH1251125998

Biotechnology & Medical Research

End-of-day quote Swiss Exchange Other stock markets 06:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
1.215 ^CHF	-3.57%		-3.57%	-38.94%

Mar. 22	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT
Mar. 22	Sector Update: Health Care	MT

Relief Therapeutics Holding AG Reports Earnings Results for the Half-Year Ended June 30, 2021

September 24, 2021 at 01:00 am EDT

Relief Therapeutics Holding AG reported earnings results for the half-year ended June 30, 2021. For the period, the operating loss amounted to CHF 14.5 million. Net loss for the period was CHF 14.7 million compared to profit of CHF 8.3 million a year ago.

Latest news about Relief Therapeutics Holding SA

Sector Update: Health Care Stocks Steady Pre-Bell Friday	Mar. 22	MT
Sector Update: Health Care	Mar. 22	MT
Eton Pharmaceuticals Acquires US Rights to Phenylketonuria Dietary Management Product	Mar. 22	MT
Relief Therapeutics Grants Eton Pharmaceuticals Exclusive License for US Commercialization of Golike	Mar. 22	MT
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE	Mar. 22	CI
Relief Therapeutics Extends CHF50 Million Share Subscription Facility with Largest Shareholder	Feb. 28	MT
Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor	Feb. 27	CI
Relief Therapeutics to Run Commercial Operations Via Partnership Model	Dec. 05	MT
Relief Therapeutics CEO to Leave; Interim Successor Takes Over	Nov. 22	MT
Relief Therapeutics Holding Sa Announces CEO Changes	Nov. 22	CI
Relief Therapeutics Meets Outstanding ADR Requirement for Nasdaq Listing	23-10-10	MT
Relief Therapeutics Holding AG(SWX:RLF) dropped from S&P Global BMI Index	23-09-18	CI
Relief Therapeutics Holding AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-15	CI
Relief Therapeutics Posts Wider H1 Loss; Revenue Down	23-09-15	MT
Relief Therapeutics Sells License for Urea Cycle Disorder Drug to Acer Therapeutics	23-08-31	MT
Relief Therapeutics Holding AG Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics	23-08-30	CI
Relief Therapeutics Announces Extension of Distribution Agreement for Pku Golike®? in the U.S. with Pentec Health	23-07-19	CI
Relief Therapeutics Extends US Distribution Deal with Pentec Health for PKU GOLIKE	23-07-19	MT
SIX Group Makes Index Adjustments Following Review	23-07-11	MT
Relief Therapeutics Entrusts Middle Eastern Distribution of PKU GOLIKE to World Orphan Drug Alliance	23-06-23	MT
Relief Therapeutics Secures CHF5 Million Capital Injection from Healthcare-focused Investor	23-06-23	MT
Relief Therapeutics Holding AG announced that it has received CHF 4.9947 million in funding	23-06-22	CI
Relief Therapeutics Targets CHF5 Million Gross Proceeds via Private Placement	23-06-16	MT
Relief Therapeutics Holding AG announced that it expects to receive CHF 4.995 million in funding	23-06-15	CI
Relief Therapeutics Holding AG announced that it expects to receive CHF 5 million in funding	23-06-15	CI

Chart Relief Therapeutics Holding SA

Duration

Period

More charts

Company Profile

RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Companyâs objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-04-26 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RELIEF THERAPEUTICS HOLDING SA	-38.94%	17.34M
IQVIA HOLDINGS INC.	-1.42%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.97%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.82%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.55%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.07%	11.68B
MEDPACE HOLDINGS, INC.	+21.36%	11.6B
UNITED THERAPEUTICS CORPORATION	+8.20%	11.15B

Other Biotechnology & Medical Research